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ABSTRACT 
Aim: Levels of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) are robustly increased in 
spinal muscular atrophy (SMA) patient fibroblasts and mouse models.  We therefore wanted 
to establish whether changes in UCHL1 contribute directly to disease pathogenesis, and to 
assess whether pharmacological inhibition of UCHL1 represents a viable therapeutic option 
for SMA. 
 
Methods:  SMA mice and control littermates received a pharmacological UCHL1 inhibitor 
(LDN-57444) or DMSO vehicle. Survival and weight were monitored daily, a righting test of 
motor performance was performed, and motor neuron loss, muscle fibre atrophy and 
neuromuscular junction pathology were all quantified. Ubiquitin-like modifier activating 
enzyme 1 (Uba1) was then pharmacologically inhibited in neurons in vitro to examine the 
relationship between Uba1 levels and UCHL1 in SMA. 
 
Results: Pharmacological inhibition of UCHL1 failed to improve survival, motor symptoms, 
or neuromuscular pathology in SMA mice and actually precipitated the onset of weight loss. 
LDN-57444 treatment significantly decreased spinal cord mono-ubiquitin levels, further 
exacerbating ubiquitination defects in SMA mice. Pharmacological inhibition of Uba1, levels 
of which are robustly reduced in SMA, was sufficient to induce accumulation of UCHL1 in 
primary neuronal cultures.  
 
Conclusion: Pharmacological inhibition of UCHL1 exacerbates rather than ameliorates 
disease symptoms in a mouse model of SMA. Thus, pharmacological inhibition of UCHL1 is 
not a viable therapeutic target for SMA.   Moreover, increased levels of UCHL1 in SMA 
likely represent a downstream consequence of decreased Uba1 levels, indicative of an 
attempted supportive compensatory response to defects in ubiquitin homeostasis caused by 
low levels of SMN protein.  
 
List of abbreviations for reference: 
SMA: Spinal Muscular Atrophy 
SMN: Survival Motor Neuron 
UCHL1: Ubiquitin carboxyl-terminal hydrolase L1 
Uba1: Ubiquitin-like modifier-activating enzyme 1 
UPS: ubiquitin proteasome system 
DUB: deubiquitinating enzyme 
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INTRODUCTION 
Spinal muscular atrophy (SMA) is a neuromuscular disorder that, with an incidence of ~1 in 
6,000 to 1 in 10,000 live births, is a leading genetic cause of infant death (1, 2). SMA is an 
autosomal recessive disease caused by homozygous disruption of the survival motor neuron 1 
gene (SMN1) (3), which results in the hallmark symptoms of lower motor neuron 
degeneration, muscle atrophy and progressive paralysis (2). The survival motor neuron 
(SMN) protein is ubiquitously expressed and has well characterised functions in spliceosomal 
small nuclear ribonucleoprotein assembly and pre-mRNA splicing (4). A second almost 
identical gene, survival motor neuron 2 (SMN2) is present in humans (3), however, due to a 
single base pair difference in exon 7, the majority of SMN2 mRNA transcripts are 
alternatively spliced and produce a rapidly degraded truncated version of the SMN protein 
called SMNΔ7 (5, 6). Therefore, only a small proportion of the full-length functional SMN 
protein as generated by SMN2 is ultimately translated in SMA patients (2). SMA disease 
severity is dependent on the amount of functional SMN protein and therefore inversely 
correlated to SMN2 copy number (7-9). Clinically, SMA can be classified in to four main 
types, based principally on the age of onset and ability to reach motor milestones. The most 
severe form (Type I; with patients possessing one or two SMN2 copies) affects infants under 
six months with death usually occurring in the first two years of life (10). Recent advances in 
translational research have identified potential SMN-dependent and SMN-independent 
modifiers and therapies for SMA (11-14). However, at present no effective treatments are 
available (15).  
 
Dysregulation of the ubiquitin proteasome system (UPS) is involved in the pathogenesis of 
many neurodegenerative diseases (16) and targeting specific components of the UPS may 
provide a promising strategy for a variety of neurodegenerative disorders, including SMA  
(17, 18). Many proteins, including SMN (19), are regulated by the UPS, where targeting to 
the proteasome occurs by way of linkage of poly-ubiquitin chains to the target protein, 
mediated by three ubiquitinating enzymes known as E1 (ubiquitin-activating), E2 (ubiquitin-
conjugating) and E3 (ubiquitin ligase) (20, 21). Protein ubiquitination is a reversible process 
and is highly regulated by a specific class of proteases, known as deubiquitinating enzymes 
(DUBs), which cleave ubiquitin from protein substrates (12, 22). Pharmacological inhibition 
of the proteasome has been shown to increase SMN levels in vitro and in vivo (23). 
Moreover, abnormal granular ubiquitin deposits have also been reported in ballooned lower 
motor neuron cell bodies and higher brain structures of SMA patients (24, 25). 
 
We recently demonstrated widespread disruption of ubiquitin homeostasis in mouse models 
of SMA (26), including significantly reduced levels of the ubiquitin-like modifier activating 
enzyme 1 (Uba1) and increased levels of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) 
(26). UCHL1 has previously been shown to regulate SMN protein levels in cell culture 
experiments, where over-expression of UCHL1 reduced SMN levels and conversely 
pharmacological inhibition or UCHL1 specific knockdown significantly increased SMN 
expression (27). Importantly, elevated levels of UCHL1 have also been reported in fibroblasts 
from SMA patients (27). UCHL1 is a highly-conserved DUB that is strongly expressed in A
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neuronal cells (28). It is one of the most abundant proteins in the brain, making up 1-2% of 
the total soluble fraction (29). UCHL1 acts as a deconjugating enzyme releasing monomeric 
ubiquitin through its C-terminal hydrolytic activity (30), however, it also has reported ligase 
activity (31) and can also act as a monoubiquitin stabiliser (32).  UCHL1 has been implicated 
in the pathology of several other neurodegenerative disorders including Alzheimer’s disease 
(33, 34), Parkinson’s disease (35-39), and an early onset progressive neurodegenerative 
syndrome (40).  
 
Taken together, the previous studies showing increased levels of UCHL1 in SMA animal 
models and patient cells suggest that UCHL1 may be contributing to disease pathogenesis 
and that inhibition of UCHL1 may therefore offer an attractive therapeutic approach for the 
treatment of SMA. The aim of this study was to investigate the role of UCHL1 in disease 
pathogenesis and to establish whether pharmacological inhibition of UCHL1 would improve 
survival and motor symptoms in an established mouse model of severe SMA. We show that 
pharmacological inhibition of UCHL1 in SMA mice had no effect on SMN levels in vivo and 
did not improve survival or motor symptoms, but rather precipitated the onset of weight loss. 
We also demonstrate that increased levels of UCHL1 observed in SMA are actually, at least 
in part, a downstream consequence of decreased levels of Uba1, suggestive of an attempted 
compensatory response to defects in ubiquitin homeostasis caused by low levels of SMN.  
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MATERIALS AND METHODS 
Ethics statement 
Experimental procedures conducted in this study were performed in accordance with the UK 
Animals (Scientific Procedures) Act 1986. All animal experiments were approved by a 
University of Edinburgh internal ethics committee and were performed under Home Office 
project license numbers 60/3891 and 60/4569. For primary cell culture of human fibroblasts, 
informed consent was previously obtained from all patients and their parents.  
 
SMA patient and control fibroblast cell culture 
Human fibroblasts were previously obtained from skin biopsies from three SMA Type I 
patients: ML 16, ML 17, ML 83 and three age matched unaffected controls: ML 24, ML 32, 
ML 44. Molecular analysis confirmed that all SMA patients had homozygous deletion of 
SMN1. Cells were maintained in high glucose Dulbecco’s modified Eagle medium (DMEM) 
(Gibco, Invitrogen) supplemented with 10% heat inactivated foetal bovine serum (HyClone, 
Thermo Scientific) and 100U/ml penicillin and 100mg/ml streptomycin (Gibco, Invitrogen). 
Fibroblasts were expanded and harvested for protein on or below passage eight.  
 
SMA mouse model 
The ‘Taiwanese’ model of severe SMA (Smn-/-; SMN2tg/0) (41, 42) was used for the in vivo 
characterisation of pharmacological UCHL1 inhibition in these experiments. Taiwanese mice 
represent a good model for pre-clinical SMA drug testing as their increased lifespan 
(compared to other severe SMA mouse models) enables a longer drug dosing regime and 
motor function tests to be performed (26, 42, 43). Taiwanese SMA mice on a congenic FVB 
background were originally obtained from Jackson Laboratories and maintained under 
standard SPF conditions at the University of Edinburgh. Phenotypically normal heterozygous 
Smn
+/-
; SMN2
tg/0
 littermates were used as controls.  
 
UCHL1 immunohistochemistry 
Following termination by overdose of anaesthetic, the vertebral columns and gastrocnemius 
muscles were rapidly dissected from P10 SMA and control mice and fixed overnight in 4% 
paraformaldehyde in phosphate buffered saline (PBS), before being transferred to a 30% 
sucrose solution overnight at 4 °C for cryoprotection. Tissue was embedded in optimal 
cutting temperature compound (OCT) and stored at -80 °C before being sectioned at 20 µm 
using a cryostat and collected directly on to slides. Sections were blocked in IgG and 
protease-free standard blocking solution (0.2% bovine serum albumin [BSA], 0.5% Triton X-
100 in PBS) for 30 min at room temperature before overnight incubation with rabbit anti-
mouse UCHL1 primary antibody (1:500 diluted in blocking solution, Novus Biologicals, 
Cambridge, UK, NB300-676) at 4 °C. After 6 x 5min washes in PBS, sections were 
incubated with swine anti-rabbit IgG TRITC secondary antibody (1:100 diluted in PBS, 
DAKO, Denmark, R0156) for 1h at 4 °C and then mounted and cover slipped in a 10% 
Mowoil solution (Polyscience). Secondary only control sections were treated in an identical 
manner except for the exclusion of primary antibody (Supplementary Figure S1). Sections 
were viewed using an inverted Olympus 1X71 microscope with either a 10x or 20x objective A
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and images taken using a digital CCD camera (Hamamatsu C4742-95) and OpenLab 
(Improvision) image capture software.  
 
UCHL1 inhibitor administration 
LDN-57444 (Calbiochem) is an isatin O-acyl oxime compound that acts as a potent, 
reversible, competitive, and active site-directed inhibitor of UCHL1 (Ki = 0.40 µM; IC50 = 
0.88 µM) with ~28-fold greater selectivity over UCHL3. LDN-57444 was dissolved in 
dimethyl sulfoxide (DMSO) and administered 0.5 mg/kg, twice daily to SMA and control 
mice via intraperitoneal (i.p) injection from the day of birth (P1). This dose was based on 
previous studies reporting this concentration to be effective in vivo (34, 44). The same 
volume of DMSO was administered by i.p injection to SMA and littermates as a vehicle-only 
control. Litters were randomly assigned to either LDN-57444 or vehicle only treatment 
groups. Survival and weight were monitored on a twice-daily basis. The age of weight loss 
onset was defined as the first day at which an individual animal showed a reduction in body 
weight. Mice were retroactively genotyped using standard PCR methods (42, 45). 
 
Motor performance test 
To assess the impact of UCHL1 inhibition on motor performance a righting reflex test was 
performed on mice at P3, P6 and P9. The righting reflex is a commonly used (26, 46), simple 
assay to assess motor ability in neonatal mice and was performed by placing a mouse on its 
back on a flat surface and measuring the time taken to turn over onto its paws (46). If a 
mouse did not respond within 60 seconds the test was terminated.   
 
Primary hippocampal neuronal culture 
E17 rat hippocampal neurons were cultured in Basal Medium Eagle (BME) serum free 
medium complemented with 1.6% of a 32.5% glucose solution, 1% Sodium Pyruvate 100 nM 
solution, 1% N-2 supplement and 5% B27 supplement. Cells were plated in a12-well plate 
and kept in 1ml of media. The cells were treated with 50uM UBEI-41, a cell-permeable 
ubiquitin E1 inhibitor (26) with an IC50 ~ 5 µM (Biogenova) dissolved in DMSO or DMSO 
only vehicle control for 2 hours before the cells were harvested by lysing the cells using 
Radio-Immunoprecipitation Assay (RIPA) buffer.  
 
Protein extraction and concentration determination 
To determine UCHL1 protein levels in SMA mice and control littermates, whole spinal cord 
tissue and gastrocnemius muscle was quickly dissected and frozen on dry ice. To establish if 
the LDN-57444 dosing regieme was effective at altering ubiquitin or SMN levels in vivo, 
whole spinal cord tissue was dissected from P10 mice which had been treated twice daily 
with LDN-57444 or vehicle. All protein extracted from tissue and cell lysate was 
homogonised and extracted in RIPA buffer (ThermoScientific) with protease inhibitor 
cocktail (Sigma) and the protein concentration determined by BCA assay (ThermoScientific).   
 
Quantitative fluorescent western blot analysis 
Extracted protein was separated by SDS–polyacrylamide gel electrophoresis on 4–20% 
precast NuPage 4–12% BisTris gradient gels (Invitrogen) and then transferred to PVDF 
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membrane by the iBlot 7 minute semi-dry blotting system (Invitrogen). Total protein levels 
were determined by incubation of each blot in a solution of Ponceau S (0.2% Ponceau, 30% 
acetic acid). PVDF membranes were then placed in blocking solution (Li-Cor) for 30 min at 
room temperature and quantitative western blots performed using primary antibodies against 
rabbit anti-mouse UCHL1 (1:2000, Novus Biologicals, NB300-676), mouse anti-ubiquitin 
(1:1000, clone Uba-1 [aka 042691GS], Merck Millipore, MAB1510), mouse anti-human 
SMN (1:1000, BD Biosciences) and mouse anti-beta-actin (1:1000, Abcam, Ab8226) all 
diluted in blocking solution overnight at 4 
o
C. Following 6 x 5min washes in PBS, Odessey 
secondary antibodies (goat anti-rabbit IRDye 680 or donkey anti-mouse IRDye 680, LI-COR 
Biosciences) were diluted in blocking buffer according to the manufacturers’ instructions and 
added to membranes for 1 hour at room temperature. Blots were washed for 6 x 5min in PBS, 
dried and imaged using an Odyssey Infrared Imaging System (Li-COR, Biosciences). Each 
blot was scanned and fluorescent band intensity measured in triplicate to minimise user 
variability. Due to alteration in the expression levels of many standard loading control 
proteins in SMA tissues (47), total protein levels, as measured by Ponceau S, were used as a 
loading control. 
 
Motor neuron cell body counts 
Mice were sacrificed at P8 (N=4 per genotype/treatment) and the spinal column was removed 
before immersion in a 4% paraformaldehyde (in PBS) solution overnight at 4
o
C. The spinal 
cord was then removed from the column and placed in a 30% sucrose solution overnight for 
cryoprotection. The lumbar enlargement was then dissected and placed in OCT, frozen on dry 
ice and stored at -80
o
C. 20µM sections were cut on a cryostat and every fourth section 
collected onto superfrost slides. For Nissl staining, slides were brought to room temperature, 
rinsed in water, dehydrated through graded alcohols (70%, 90% and 100% ethanol) before 
being paced in xylene for 10 minutes. Sections were then rehydrated back down the graded 
alcohols and water before being stained in 0.2% Cresyl Fast Violet containing 1% acetic acid 
for 7 minutes. Following dehydration through graded alcohol solutions and xylene, slides 
were cover-slipped using DPX mounting media. Phase contrast images of the ventral horn 
were taken using an inverted Olympus 1X71 microscope with a 4x objective and images 
taken using a digital CCD camera (Hamamatsu C4742-95) and OpenLab (Improvision) 
image capture software. Counts of motor neuron cell soma were performed by an investigator 
blind to the genotype and treatment status of each specimen, as previously described (26). 
 
Neuromuscular junction immunohistochemistry  
Mice were sacrificed at P8 (N=3 per genotype/treatment) and the levator auris longus (LAL) 
and transversus abdominis (TVA) muscles were dissected and immunohistochemically 
labelled as previously described (45). Counts of the number of motor axons innervating each 
neuromuscular junction were performed by an investigator blind to the genotype and 
treatment status of each specimen, as previously described (26). 
 
Muscle fibre diameter measurements  
Mice were sacrificed at P8 (N=3 per genotype/treatment) and whole-mount teased fibre 
preparations of LAL and TVA muscles were prepared as previously described (26). Phase 
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contrast images of isolated single muscle fibres were taken using an inverted Olympus 1X71 
microscope at 20x objective equipped with a digital CCD camera (Hamamatsu C4742-95) 
and OpenLab (Improvision) image capture software. Muscle fibre diameters were measured 
using ImageJ software by an investigator blind to the genotype and treatment status of each 
specimen, as previously described (26). 
 
Statistical analysis 
Data were analysed using Microsoft Excel and GraphPad Prism software. All data are 
reported as mean  SEM. Individual statistical tests used are detailed in figure legends. 
Statistical significance was considered to be P ≤ 0.05 for all analyses. Figures were created 
using Adobe Photoshop.   
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RESULTS  
Increased UCHL1 levels in Type I SMA patient fibroblasts 
In order to confirm previous reports of elevated UCHL1 levels in SMA patients (27), western 
blot analysis was performed on protein extracted from Type I SMA primary patient 
fibroblasts and fibroblasts from unaffected controls. UCHL1 was found to be significantly 
increased in Type I SMA patient fibroblasts compared to unaffected controls (control 100% ± 
48.8% vs. SMA 6000% ± 671.9&, N = 3, P < 0.01) (Figure 1A and B), with a similar large 
magnitude of change to that previously reported by Hsu and colleagues (27). 
 
UCHL1 levels are increased in SMA mouse spinal cord and muscle 
As well as data from SMA patient fibroblasts (27), previous studies have demonstrated 
increased levels of UCHL1 in isolated synaptic preparations from the ‘severe’ mouse model 
of SMA (26). Initially, therefore, we wanted to establish whether UCHL1 levels were 
similarly increased throughout the neuromuscular system of the ‘Taiwanese’ mouse model of 
SMA (42). Western blot analysis of whole spinal cord and gastrocnemius muscle protein 
from ‘Taiwanese’ SMA mice compared to unaffected littermate controls at P10 revealed that 
UCHL1 levels were significantly elevated in the spinal cord (control 100% ± 9.1%, N=4 vs. 
SMA 269.0% ± 18.3%, N=4, P < 0.005) (Figure 2A and B) and muscle (control 100% ± 
12.1%, N=3 vs. SMA 304.3% ± 41.2%, N=4, P < 0.01) (Figure 2D and E). Similarly, 
increased levels of UCHL1 were present in the ventral horn of spinal cord and gastrocnemius 
muscle from ‘Taiwanese’ SMA mice compared to littermate controls when visualised using 
immunohistochemical techniques (Figure 2C and F). A temporal analysis of UCHL1 levels in 
muscle revealed significantly elevated UCHL1 levels present from early- through to late-
symptomatic time points (P4: control 100% ± 13.5%, N=3 vs. SMA 142.8% ± 20.2%, N=3, P 
< 0.05, P7: control 100% ± 33.9%, N=3 vs. SMA 220.5% ± 52.0%, N=3, P < 0.05), but not at 
a pre-symptomatic age (P1: control 100% ± 28.1%, N=3 vs. SMA 95.8% ± 24.6%, N=3) 
(Figure 2G).  
 
Pharmacological inhibition of UCHL1 reduced ubiquitin levels in the SMA mouse 
spinal cord in vivo but did not affect SMN levels 
In order to determine the effects of inhibiting UCHL1 on SMA pathogenesis in vivo, we 
identified LDN-57444 as a potent pharmacological inhibitor. Treatment with LDN-57444 has 
been shown to significantly reduce ubiquitin levels in the mouse brain (44), with 
measurement of mono-ubiquitin levels established as a good marker for UCHL1 in vivo 
activity (48). Whole litters of mice (including both ‘Taiwanese’ SMA mice and littermate 
controls) were dosed twice daily with 0.5 mg/kg of LDN-57444 (or vehicle only control) via 
intraperitoneal (i.p) injection, starting at the day of birth. Litters were randomly assigned to 
either LDN-57444 or vehicle only treatment groups. 
 
Mono-ubiquitin levels were measured using quantitative western blot analysis on whole 
spinal cord tissue from animals culled at P10. Pharmacological inhibition of UCHL1 
significantly reduced levels of monomeric ubiquitin by ~20% in vivo compared to vehicle 
controls (Figure 3A and B). This is a similar reduction to that previously reported in neurons A
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treated with LDN-57444 in vitro (48), indicating that the dosing regime was effective at 
inhibiting UCHL1 hydrolase activity in SMA mice in vivo. In contrast to previous SMA 
fibroblast in vitro data (27), pharmacological inhibition of UCHL1 did not increase SMN 
levels in SMA mice in vivo (vehicle 100% ± 22.83% vs. LDN-57444 99.29% ± 28.53%, 
N=3) (Figure 3C and D). 
 
Pharmacological inhibition of UCHL1 failed to improve weight or survival of SMA 
mice, and precipitated the onset of weight loss 
To establish the effect of pharmacological inhibition of UCHL1 on SMA mice, we initially 
measured the weight of SMA mice daily from birth. Treatment with LDN-57444 did not 
modify the average daily weight of SMA mice (Figure 4A), nor did it modify the average 
daily weight of littermate control mice (Figure 4A). However, the age at which weight loss 
was first observed in SMA mice (an indicator of overt disease onset) was significantly 
reduced in the LDN-5744 treated animals, suggesting that UCHL1 inhibition actually had a 
detrimental impact on disease progression (P < 0.05) (Figure 4C).  
 
Next, we performed a survival analysis on LDN-57444 and vehicle-only control treated SMA 
mice. The survival curve of LDN-57444 treated mice was shifted to the left of the vehicle 
treated curve (Figure 4B), indicating that if anything LDN-57444 was precipitating the onset 
of disease, although the median survival did not reach statistical significance (median age of 
death of vehicle treated SMA mice was P11, N=11 vs. P10 for LND-57444 treated SMA 
mice, N=10) (Figure 4B).  
 
Pharmacological inhibition of UCHL1 did not improve motor performance of SMA 
mice 
To further assess the impact of UCHL1 inhibition on neuromuscular phenotypes in SMA 
mice, we monitored motor performance using the righting reflex test at postnatal day three 
(P3), six (P6) and nine (P9). At P3 there was no significant difference between the righting 
times observed in SMA and littermate control mice, with LDN-57444 having no observable 
effect (Figure 4A). However, at P6 and P9 both SMA vehicle and SMA LDN-57444 treated 
mice performed significantly worse than control vehicle and control LDN-57444 treated mice 
(for all comparisons P < 0.05) (Figures 5B and C). At all three time points LDN-57444 
administration had no significant impact on the motor performance of SMA mice (Figure 5A, 
B and C). At P6 vehicle treated SMA mice took 9 ± 2 seconds to right (N=15), whereas 
LDN-57444 treated SMA mice took 8 ± 2 seconds (N=9) (Figure 5B). At P9 the average 
righting time was 7 ± 3 seconds (N=11) for vehicle treated SMA mice compared to 9 ± 2 
seconds for LDN-57444 treated SMA mice (N=6) (Figure 5C). Thus, treatment with LDN-
57444 had no measurable effect on motor performance in SMA mice. 
 
Pharmacological inhibition of UCHL1 did not improve neuromuscular pathology in 
SMA mice 
To determine whether UCHL1 inhibition was having a sub-clinical impact on underlying 
neuromuscular pathology in SMA mice, we assessed motor neuron soma loss from the 
ventral horn of spinal cord, skeletal muscle fibre atrophy and neuromuscular junction 
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pathology in LDN-57444 treated SMA mice at a late-symptomatic time-point (P8). As 
previously reported for the ‘Taiwanese’ mouse model of SMA (26, 42), there was a modest, 
but statistically significant, loss of motor neurons from the ventral horn of spinal cord at late-
symptomatic time-points compared to littermate controls (Figure 6A and B). Motor neuron 
loss was not ameliorated in SMA mice treated with LDN-57444 (Figure 6A and B; N=4 mice 
per genotype/treatment). Similarly, skeletal muscle fibre atrophy has previously been 
documented in the ‘Taiwanese’ SMA mice (26). Treatment with LDN-57444 had no 
significant impact on this process in either the LAL or TVA muscle (Figure 6C, D and E; 
N=3 mice). Likewise, treatment with LDN-57444 had no impact on the modest loss of axonal 
inputs observed from neuromuscular junctions in late-symptomatic SMA mice (Figure 6F 
and G; N=3 mice). 
 
Uba1 inhibition increased UCHL1 levels in vitro  
The observation that pharmacological inhibition of UCHL1 exacerbated, rather than 
improved, the health of SMA mice, alongside the observation that inhibition of UCHL1 led to 
a decrease in mono-ubiquitin levels in vivo (thereby phenocopying ubiquitination defects 
previously reported in SMA mice; (26)), led us to question whether increased levels of 
UCHL1 in SMA actually represent an attempted compensatory response, rather than driving 
neuromuscular pathology. We therefore wanted to establish whether increased levels of 
UCHL1 were caused by upstream changes in other aspects of the ubiquitin pathway known to 
be altered in SMA. Given that we previously demonstrated that low levels of SMN lead to 
reduced levels of the E1 ubiquitin-activating enzyme Uba1 in SMA mice (~50% of those 
seen in healthy control mouse spinal cord and ~40% of those present in healthy mouse 
skeletal muscle (26)), and that genetic or pharmacological suppression of Uba1 is sufficient 
to recapitulate SMA-like neuromuscular pathology in zebrafish (26), we examined whether 
increased levels of UCHL1 were occurring as a direct response to lowered Uba1 levels.  
 
We treated primary neurons with UBEI-41, a potent pharmacological Uba1 inhibitor (49, 50), 
for 2 hours and examined the effect on UCHL1 levels. Cells treated with UBEI-41 had 
significantly reduced mono-ubiquitin levels compared to untreated controls (Figure 7A and 
B), confirming targeting of Uba1 and downstream Uba1-dependent ubiquitination pathways 
(26). Strikingly, UCHL1 levels were robustly increased (>3-fold) in cells treated with UBEI-
41 (Figure 7A and C). Thus, pharmacological suppression of Uba1 (phenocopying the 
reduced levels of Uba1 in SMA mouse spinal cord and muscle; (26)) was sufficient to 
increase UCHL1 levels in neurons. This finding suggests that the increased levels of UCHL1 
observed in SMA are, at least in part, a downstream consequence of SMN-mediated Uba1 
suppression. Taken together with our findings regarding the negative influence of UCHL1 
inhibition on SMA mice, this suggests that increased levels of UCHL1 likely represent an 
attempted compensatory response to defects occurring elsewhere in the UPS.   
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DISCUSSION 
Previous findings from animal models of SMA and patient fibroblasts suggested that 
increased levels of UCHL1 may be contributing to disease pathogenesis in SMA, leading to 
the suggestion that inhibition of UCHL1 might offer an attractive therapeutic approach for 
the treatment of SMA (26, 27). In the present study, we confirm and extend these initial 
observations by showing that UCHL1 levels are significantly increased in the neuromuscular 
system in vitro and in vivo during SMA. However, in contrast to the initial suggestions that 
inhibition of UCHL1 might represent a therapeutic target for SMA, pharmacological 
inhibition of UCHL1 in SMA mice failed to improve survival, motor symptoms or 
neuromuscular pathology, and instead precipitated the onset of weight loss. This worsening 
of overt disease status could be explained by the observation that pharmacological inhibition 
of UCHL1 in vivo significantly decreased spinal cord mono-ubiquitin levels, thereby 
exacerbating ubiquitination defects previously reported in SMA mice (26). This finding, 
together with the known DUB role of UCHL1, suggests that the increased UCHL1 levels 
present in SMA actually represent an attempted compensatory response to help increase and 
restore ubiquitin homeostasis. We demonstrated that pharmacological inhibition of the E1 
enzyme Uba1 in primary neuronal cell culture, phenocopying the situation observed in SMA 
mouse spinal cord and muscle (26), was sufficient to robustly increase UCHL1 expression in 
vitro. This indicates that the increased levels of UCHL1 observed in SMA are, at least in part, 
a downstream consequence of Uba1 suppression and are likely to represent a response to 
upstream defects in ubiquitin homeostasis previously shown to be caused by low levels of 
SMN (26). 
 
Maintenance of ubiquitin homeostasis is crucial to nervous system development and function 
(51) with DUBs such as UCHL1 playing crucial roles in the conservation of ubiquitin levels 
and prevention of inappropriate target degradation by the proteasome (52). The importance of 
UCHL1 activity to the nervous system is underscored by the association of several UCHL1 
loss-of-function mutations with neurodegenerative diseases and the neurodegenerative 
phenotypes reported in experimental models of UCHL1 inhibition. The G7A missense 
mutation in the UCHL1 gene reduces ubiquitin binding affinity causing a near complete loss 
of UCHL1 hydrolytic activity and is linked to a severe early-onset neurodegenerative 
syndrome (40). Similarly, the I93M UCHL1 mutation, which confers a 50% reduction in 
catalytic activity, has been reported in a family with autosomal dominant Parkinson’s disease 
(35) with expression of the I93M mutant in transgenic mice leading to the degeneration of 
dopaminergic neurons (53). Conversely, the S18Y polymorphism variant of UCHL1, which 
has comparable hydrolase but reduced ligase activity, has been associated with a decreased 
Parkinson’s disease risk (31, 54). Down-regulation of UCHL1 has been reported in 
Alzheimer’s disease brains where the number of neurofibrillary tangles is inversely 
proportional to soluble UCHL1 levels (55). In the APP/Ps1 mouse model of Alzheimer’s 
UCHL1 has been shown to be important in synaptic function and contextual memory (34). In 
vitro application of LDN-57444 to hippocampal slices reduced long-term potentiation whilst 
transduction of UCHL1 protein corrected defects in synaptic transmission and improved fear 
learning in vivo (34). However, other studies have found potential beneficial effects of A
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pharmacological inhibition of UCHL1 by LDN-57444 for Parkinson’s disease treatment by 
enhancing clearance and reducing alpha-synuclein levels (44). Interestingly, in non-
transgenic animals and neuronal cells with endogenous UCHL1 levels LDN-57444 treatment 
produced the opposite effect on alpha-synuclein distribution, highlighting the different effects 
UCHL1 inhibition can have under normal and pathological conditions (44).  
 
UCHL1 knock-out mice present with progressive paralysis and premature death associated 
with progressive degeneration of pre-synaptic terminals and marked impairment of synaptic 
transmission at the neuromuscular junction (NMJ) (56). Similarly, ubiquitin deficiency 
caused by loss of the DUB Usp14 in ataxia mice has been shown to cause selective 
developmental defects at the motor endplate and disruption of synaptic transmission, with 
transgenic restoration of ubiquitin levels preventing pathology (52). These striking 
similarities of NMJ vulnerability due to the loss of DUBs could be due the high demand of 
the UPS in endplate development coupled with the long distances of ubiquitin transport 
making motor neurons particularly vulnerable to local fluctuations in ubiquitin levels (52). 
Interestingly, NMJ denervation caused by loss of presynaptic inputs is also observed in early 
symptomatic SMA mice (45). A spontaneous mutation in the Uch-L1 gene, which causes loss 
of detectable UCHL1 protein expression, is present in gracile axonal dystrophy (gad) mice 
(57). Gad mice display progressive accumulation ubiquitinated protein conjugates alongside 
axonal degeneration of the gracile tract along with motor paresis (58). Recently, it has also 
been shown that eGFP expression driven by the Uch-L1 promoter genetically labels a 
subpopulation of degeneration resistant spinal motor neurons in a mouse model of 
amyotrophic lateral sclerosis (59). Together, these findings indicate that the increased 
UCHL1 levels observed in SMA may in fact represent an attempted compensatory response 
to defects occurring elsewhere in the UPS (e.g. to Uba1), and may therefore actually 
represent an attempted neuroprotective response (akin to the situation reported in 
amyotrophic lateral sclerosis (59)). Such a scenario would help explain the detrimental 
impact of inhibiting UCHL1 hydrolase activity in SMA mice found in the current study. 
Thus, studies examining the influence of increased levels of UCHL1 on SMA pathology may 
now be warranted. However, targeting other aspects of UPS dysfunction that are directly 
contributing to disease pathogenesis (e.g. Uba1 suppression (26)) may prove to be more 
beneficial in the long run for developing novel SMA therapeutics. 
 
In conclusion, we have demonstrated that pharmacological inhibition of UCHL1 exacerbates 
rather than ameliorates disease symptoms in a mouse model of SMA. As a result, 
pharmacological inhibition of UCHL1 is not a viable therapeutic target for the treatment of 
SMA.  Rather, we showed that increased levels of UCHL1 in SMA represent, at least in part, 
a downstream consequence of decreased Uba1 levels, indicative of an attempted supportive 
compensatory response to defects in ubiquitin homeostasis caused by low levels of SMN 
protein. This provides further insights into the complex nature of perturbations in ubiquitin 
homeostasis driving disease pathogenesis in SMA. 
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FIGURE LEGENDS 
 
Figure 1. Increased UCHL1 levels in Type I SMA patient primary fibroblasts. A. Top 
panel shows representative fluorescent western blot bands for UCHL1 protein from primary 
fibroblasts from three individual Type I SMA patients and unaffected controls. Order of 
lanes: Control ML 32, SMA ML 83, Control ML 44, SMA ML17, Control ML 24, SMA ML 
16.  Ponceau S loading control is shown in the bottom panel. B. Bar chart showing 
quantification of UCHL1 fluorescent western blot band intensity in SMA and control human 
fibroblast samples, normalized to Ponceau S (N=3 fibroblast samples per genotype; **P < 
0.01; two-tailed unpaired Student’s t-test).  
 
Figure 2. Increased UCHL1 levels in ‘Taiwanese’ SMA mouse spinal cord and skeletal 
muscle. A & D. Middle panel shows representative fluorescent western blot bands for 
UCHL1 protein in whole (A) spinal cord and (D) muscle protein extract from P10 SMA and 
control mice. Ponceau S loading control is shown in the bottom panel. The genotype of the 
corresponding mice, as analysed by PCR, is shown in the top panel. B & E. Bar chart 
showing quantification of UCHL1 fluorescent western blot band intensity in SMA and 
control mice, normalised to Ponceau S, in spinal cord (B) (N=4 mice per genotype; ***P < 
0.005; two-tailed unpaired Student’s t-test) and muscle (E) (N=3 mice per genotype; **P < 
0.01; two-tailed unpaired Student’s t-test). C & F. Immunohistochemical staining of UCHL1 
in the (C) ventral horn of the spinal cord and (F) gastrocnemius muscle of P10 control and 
SMA mice. Micrographs were obtained from tissue processed in an identical manner and 
with identical microscope settings for control and SMA tissue. Scale bars represent 200µm 
for spinal cord and 100µm for muscle images. G. Graph showing UCHL1 levels in the 
gastrocnemius muscle of control and SMA mice at P1, P4, P7 and P9 measured using 
quantitative fluorescent western blot (N=3 mice per genotype; **P < 0.01, *P < 0.05, ns = 
not significant; two-tailed unpaired Student’s t-test). 
 
Figure 3. Pharmacological inhibition of UCHL1 reduces mono-ubiquitin levels but has 
no effect on SMN levels in SMA mouse spinal cord in vivo. A & C. Representative 
fluorescent western blots showing (A) mono-ubiquitin levels and (C) SMN levels from whole 
spinal cord protein extract from vehicle and LDN-57444 treated P10 SMA mice. Ponceau S 
loading control is shown in the bottom panels. Mice were administered with 0.5 mg/kg LDN-
57444 dissolved in DMSO twice daily via intraperitoneal injection from the day of birth. The 
same volume of DMSO alone was used as a vehicle-only control. B & D. Bar chart showing 
quantification of (B) mono-ubiquitin levels and (D) SMN levels in vehicle and LDN-57444 
treated mice (N=3 mice per treatment group; * P < 0.05, ns = not significant; two-tailed 
unpaired Student’s t-test).  
 
Figure 4. Pharmacological inhibition of UCHL1 failed to improve weight or survival of 
SMA mice, and precipitated the onset of weight loss. A. Graph showing average weights 
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of vehicle and LDN-57444 treated SMA mice, as well as vehicle and LDN-57444 treated 
littermate control mice, from the day of birth. Mice were administered with 0.5 mg/kg LDN-
57444 dissolved in DMSO or DMSO vehicle control twice daily via intraperitoneal injection 
from P1. B. Survival curves showing percentage survival of vehicle and LDN-57444 treated 
SMA mice, as well as vehicle and LDN-57444 treated littermate control mice. Survival 
curves for vehicle treated SMA mice and LDN-57444 treated SMA mice showed no 
significant difference when compared using a log-rank (Mantel-Cox) test. Median age of 
death of vehicle treated SMA mice was P11 (N=11) compared to P10 for LND-57444 treated 
SMA mice (N=10). C. Bar chart comparing age of onset of weight loss in vehicle treated 
SMA mice with LDN-57444 treated SMA mice. Data shown as mean ± SEM. The mean age 
of onset of weight loss was significantly reduced in LDN-57444 treated SMA mice compared 
to vehicle treated mice (N=11 vehicle treated mice, N=10 LDN-57444 treated mice; * P < 
0.05; two-tailed unpaired Student’s t-test).  
 
Figure 5. Pharmacological inhibition of UCHL1 had no effect on motor performance of 
SMA mice. A-C. Bar charts showing the time taken for littermate control vehicle treated 
mice, littermate control LDN-57444 treated mice, SMA vehicle treated mice and SMA LDN-
57444 treated mice to right themselves onto their paws once placed on their back at (A) P3, 
(B) P6 and (C) P9. Data are shown as mean ± SEM. Mice were administered with 0.5 mg/kg 
LDN-57444 dissolved in DMSO or DMSO only control twice daily via intraperitoneal 
injection from the day of birth (P3: control vehicle treated mice, N=19; control LDN-57444, 
N=15; SMA vehicle, N=17; SMA LDN-57444, N=10) (P6 control vehicle, N=16; control 
LDN-57444, N=12; SMA vehicle, N=15; SMA LDN-57444, N=9) (P9: control vehicle, 
N=16; control LDN-57444, N=12; SMA vehicle, N=11; SMA LDN-57444, N=6). Statistical 
comparisons were made using ANOVA with Turkey’s post hoc comparisons test (ns = not 
significant). D-F. Representative photographs of control vehicle, SMA vehicle and SMA 
LDN-57444 treated mice at (D) P3, (E) P6 and (F) P9. 
 
Figure 6. Pharmacological inhibition of UCHL1 had no effect on neuromuscular 
pathology in SMA mice. A. Representative micrographs of motor neuron cell soma in the 
ventral grey horn of spinal cord from littermate control and SMA mice at P8 treated with 
LDN-57444 or vehicle control. B. Bar chart comparing number of motor neuron soma in 
SMA and littermate control mice treated with LDN-57444 or vehicle control. As expected, 
the mean number of motor neurons was significantly reduced in vehicle treated SMA mice 
compared to vehicle treated littermate controls (N=4 mice per treatment/genotype; ** P < 
0.01; ANOVA with Turkey’s post hoc test). There was no significant difference between 
LDN-57444 treated and vehicle treated SMA mice (ns P > 0.05). C. Representative phase 
contrast micrographs of single teased muscle fibres from the TVA muscle of littermate 
control and SMA mice at P8 treated with LDN-57444 or vehicle control. D-E. Bar charts 
comparing muscle fibre diameters in the TVA (D) and LAL (E) muscle from SMA and 
littermate control mice treated with LDN-57444 or vehicle control. As expected, the mean 
muscle fibre diameter was significantly reduced in vehicle treated SMA mice compared to 
vehicle treated littermate controls for both muscles (N=3 mice per treatment/genotype; ** P < 
0.01; *** P < 0.001; ANOVA with Turkey’s post hoc test). There was no significant 
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difference between LDN-57444 treated and vehicle treated SMA mice in either muscle 
examined (ns P > 0.05). F. Representative confocal micrographs of immunohistochemically 
labelled neuromuscular junctions (NMJs) from the caudal band of the LAL muscle of 
littermate control and SMA mice at P8 treated with LDN-57444 or vehicle control (green = 
axons and synaptic terminals; red = postsynaptic acetylcholine receptors). G. Bar chart 
comparing the average number of motor axon inputs per NMJ in SMA and littermate control 
mice treated with LDN-57444 or vehicle control. As expected, the mean number of axon 
inputs was significantly reduced in vehicle treated SMA mice compared to vehicle treated 
littermate controls (N=4 mice per treatment/genotype; * P < 0.05; ANOVA with Turkey’s 
post hoc test). There was no significant difference between LDN-57444 treated and vehicle 
treated SMA mice (ns P > 0.05). Scale bars represent 200µm for spinal cord images, 25µm 
for muscle images and 50µm for NMJ images. Data shown as mean ± SEM. 
 
Figure 7. Inhibition of Uba1 is sufficient to increase UCHL1 levels in neurons. A. 
Representative fluorescent western blot of protein levels in primary neurons treated with 
50uM UBEI-41 (a cell-permeable ubiquitin E1 inhibitor), or DMSO only vehicle control, for 
2 hours. The top panel shows mono-ubiquitin protein levels, the middle panel shows UCHL1 
protein levels and the bottom panel shows beta-actin loading control levels. (B) Bar chart 
showing levels of mono-ubiquitin protein in control and UBEI-41 treated cells (N=4 
independent experiments per treatment; ** P < 0.01; two-tailed unpaired Student’s t-test).  
(C) Bar chart showing levels of UCHL1 in control and UBEI-41 treated cells (N=4 
independent experiments per treatment, **** P < 0.001; two-tailed unpaired Student’s t-test). 
Data shown as mean ± SEM. 
Supplementary Figure 1. Secondary antibody only immunohistochemistry control.  A-
D. Secondary antibody only immunohistochemical staining of the ventral horn of the spinal 
cord of P10 control mouse (A) spinal cord, (C) muscle and SMA mouse (B) spinal cord, (D) 
muscle without inclusion of UCHL1 primary antibody. Micrographs were obtained from 
tissue processed in an identical manner and with identical microscope settings. Scale bars 
represent 200µm for spinal cord and 100µm for muscle. 
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